Inflammatory Marker Levels, Age, Race and Prior Treatment Burden | Santiago Thibaud, MD | ASH 2023

A Multicenter, Retrospective Analysis of AML Patients | Jan Bewersdorf, MD | ASH 2023

Safety and Efficacy of Cilta Cel: CARTITUDE-2 Study | Jens Hillengass, MD, PhD | ASH 2023

Importance of Caregivers for Patients with Multiple Myeloma | Hamza Hashmi | ASH 2023

Serum Biomarkers and Progression Risk in Smoldering Myeloma | Theresia Akhalghi, MD | ASH 2023

Pathogenic Germline Variants in Cancer Predisposition Genes | Santiago Thibaud, MD | ASH 2023

Investigating Prognostic Significance of Malnutrition in AML | Samuel Yates, MD, MS | ASH 2023

Unscheduled Interactions in Outpatient Bispecific Therapy for RRMM | Anna Howard, RN | ASH 2023

Benefits of Early MGUS Screening: iStopMM Study Results | Sæmundur Rögnvaldsson, MD, PhD | ASH 2023

Telehealth Program for Older Patients & Decision Preferences in AML | Jane Liesveld, MD | ASH 2023

GPRC5D Directed CAR T-Cell Therapy | University of Alabama | Susan Bal, MD | ASH 2023

Teclistamab: Outpatient Step-up Dosing and Real-World Outcomes | Tyler Sandahl, PharmD | ASH 2023

Insurance Impact on Outcomes for Rural Hematologic Patients | Kingsley Nnawuba, MD | ASH 2023

Real-World Safety and Efficacy of Teclistamab | Hamza Hashmi | ASH 2023

Efficacy of Reduced Dosing of Talquetamab in Relapsed Refractory Myeloma | Ajai Chari, MD | ASH 2023